resTORbio announces that the phase 3 PROTECTOR 1 trial of RTB101 in clinically symptomatic respiratory illness did not meet the primary endpoint

(resTORbio, Inc., 2019)

Links

Leave a Reply

Your email address will not be published. Required fields are marked *